Sentences with phrase «diagnostic assays for»

It will be extremely important to identify and characterize those viruses as quickly as possible — to get a head start on the development of diagnostic assays for surveillance and drugs, or vaccines for treatment — before they have a chance to really spread.»

Diagnostic assays for on - farm use have different constraints compared with those used in traditional laboratory environment

So we wanted to elucidate the molecular basis of that resistance in the population and design a field applicable diagnostic assay for its monitoring.»

Esko is collaborating with Zacharon Pharmaceuticals, a San Diego - based biotechnology company, to develop a commercial diagnostic assay for differentiating forms of MPS from urine and blood samples, a screening test for newborns and a tool for measuring the biochemical response of MPS patients to existing and novel therapies.

Not exact matches

NEW YORK (360Dx)-- Biotech firm Berg continued its push into cancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperplasia.

Notably, the Sierra Leonean genomes differ from PCR probes for four separate assays used for EBOV and pan-filovirus diagnostics (table S3).

Qiagen creates sample and assay technologies for use in research, applied testing, and molecular diagnostics and has about 2,600 employees worldwide.

In 2011, she joined the institution's molecular diagnostics laboratory where she has been developing translational next generation sequencing assays and bioinformatics workflows for the Molecular Tumor Profiling Lab of the Yale Cancer Center.

The Institute hopes to eventually obtain viral isolates for medical countermeasure development and receive data on the performance of the diagnostic assays.

The investigators believe the assay they developed to discover the mutation may hold promise as a diagnostic for predicting male progression to cirrhosis and liver cancer.

The prospective cohort study met both its primary endpoints: to determine the association between troponin T levels measured by a high - sensitivity troponin T assay and the risk of death within a month of non-cardiac surgery, and to identify diagnostic criteria for myocardial injury after non-cardiac surgery that defines whether or not serious injury to the heart has occurred.

The need for diagnostic devices for biodefense is not going away, Singh said, since there are always new diseases springing up that lack good diagnostic assays.

The Showe Laboratory will be performing the optimization and validation of the prototype glioblastoma diagnostic test, transferring the assay to a more versatile technology platform that is better suited for clinical applications.

• Customized mutation screening assays Biotage, the manufacturing company of the genetic analyzer PyroMark ID, offers in its database more than 1,000 customized assays for routine clinical screening diagnostics.

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

DENVER — A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the «BLUEPRINT PD - L1 IHC ASSAY COMPARISON PROJECT» at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

This effort, which will enhance deCODE's proprietary gene and drug target discovery work and may provide genetic markers for additional diagnostic development, will leverage Illumina's Sentrix ® HumanHap BeadChips; Infinium ™ assay and LIMS (laboratory information management system); as well as analysis and visualization tools from Illumina's BeadStudio software.

This assay will be a useful tool for differential Zika fever diagnostics in a situation where number of other disease like malaria, dengue, chikungunya co-circulate and are clinically indistinguishable.

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED - 2 PCR Assay.

We provide a full - range of standardized CE - marked in vitro diagnostic products for hematology - oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

As a reagent manufacturer, we offer a comprehensive selection of gel, capillary, and next - generation sequencing PCR assays for gene rearrangement, chromosome translocation, and gene mutation detection as analyte specific reagents (United States), research use only, or CE - marked in vitro diagnostics to laboratories (outside of North America).

The LymphoTrack ® Dx TRB Assay for the Illumina MiSeq ® is an in vitro diagnostic product intended for next - generation sequencing (NGS) based determination of the frequency distribution of TRB gene rearrangements in patients suspected with having lymphoproliferative disease.

Dr. Shendure's research group in Seattle pioneered exome sequencing and its earliest applications to gene discovery for Mendelian disorders (e.g. Miller and Kabuki syndrome) and autism; cell - free DNA diagnostics for cancer and reproductive medicine; massively parallel reporter assays and saturation genome editing; whole organism lineage tracing; and massively parallel molecular profiling of single cells.

Currently, Vaijayanti leads Strand's translational clinical research team that designs and validates next - generation sequencing and molecular assays for Strand's clinical diagnostics offering in personalized medicine.

The SCIEX clinical diagnostic portfolio includes an FDA - cleared assay for in vitro diagnostic use, mass spectrometers and fully integrated LC - MS / MS systems with easy to learn, intuitive software.

It is a paper based vertical flow microarray assay that could find use in future point of care affinity proteomic applications, for instance in the fields of autoimmunity, allergy, infection or cancer diagnostics.

SEngine Precision Medicine, instead, is pursuing an innovative approach for the development of novel targets and drugs for cancer therapy by using primary patient organoids initially derived for our diagnostic assay.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

With ~ 81 % of the human proteome on a single slide, ImmuneProfiler represents a more comprehensive and high - throughput alternative to other assay platforms for the development of predictive early diagnostic tests.

In order to develop field - applicable diagnostics for Vgsc CN, and as a prelude to investigating the possible association of CN with insecticide resistance, three assays were compared for their accuracy in CN estimation in this species.

Dr. Manak has helped set up and direct various collaborative programs with developers of infectious disease tests including Hologic, Roche, Bio-Rad, SpotOn and SeraCare as well as partnerships with government agencies for evaluation of diagnostic assays and devices.

Prior to Joining MHRP, Dr. Manak was the Chief Scientist of SeraCare Life Sciences Inc., where he led the development of seroconversion and performance panels widely used by the in vitro diagnostics community for development, evaluation and validation of in vitro diagnostic assays used in screening and monitoring of infectious diseases.

For eight of these 11 events, mosaicism was observed in saliva but not blood, suggesting that assaying blood alone would miss a large fraction, possibly > 50 %, of mosaic diagnostic chromosomal rearrangements.

Dr. Manak has extensive expertise in development and validation of in - house and commercial assays for HIV and related infectious diseases and their use in diagnostic, epidemiological, vaccine and therapeutic programs.

Dr. Brady worked with Diagnostic Solutions Laboratory to develop and launch the first DNA / PCR molecular assay for GI pathogens performed on stool using an FDA - approved platform and methodology, the GI Microbial Assay Plus (GI - assay for GI pathogens performed on stool using an FDA - approved platform and methodology, the GI Microbial Assay Plus (GI - Assay Plus (GI - MAP).

TRIB also acquired Fiomi Diagnostics, a Swedish company at an advanced stage in developing a panel of point - of - care cardiac marker assays, particularly for Troponin I. $ 60 mio «s already been spent on the technology, and it offers TRIB a slice of the $ 900 mio Cardiac POC diagnostics market, which is growing 14 % pa.

«Henry Schein's companion animal health distribution business is the largest in North America and our customers consistently rely on us for a comprehensive line of products and services, including a full range of veterinary diagnostics products such as instruments, consumables and rapid assays,» said Lonnie Shoff, the Chief Executive Officer of Henry Schein's Global Animal Health and Strategic Partnership Group.

Prospective Diagnostic Accuracy Evaluation and Clinical Utilization of a Modified Assay for Platelet Associated Immunoglobulin in Thrombocytopenic and Non-Thrombocytopenic Dogs.

Identification of Borrelia burgdorferi OspC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.

Typically, companies in the pharmaceutical and biotechnology industries file patents protecting small molecules, biologics (an antibody, peptide sequence, etc), methods of treatment or unique (diagnostic) assays (for detecting and / or treating disease).

Executed and documented experimental test designs for donor screening and diagnostic assays, feasibility of a new donor screening system